211 related articles for article (PubMed ID: 37720688)
41. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
Jitschin R; Saul D; Braun M; Tohumeken S; Völkl S; Kischel R; Lutteropp M; Dos Santos C; Mackensen A; Mougiakakos D
J Immunother Cancer; 2018 Nov; 6(1):116. PubMed ID: 30396365
[TBL] [Abstract][Full Text] [Related]
42. Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.
Wang L; Hu D; Xie B; Xie L
Invest New Drugs; 2022 Jun; 40(3):506-518. PubMed ID: 35089465
[TBL] [Abstract][Full Text] [Related]
43. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
44. Expansion of Monocytic Myeloid-Derived Suppressor Cells in Patients Under Hemodialysis Might Lead to Cardiovascular and Cerebrovascular Events.
Xing YF; Cai JR; Qin JJ; Zhou WY; Li CM; Li X
Front Immunol; 2020; 11():577253. PubMed ID: 33584644
[TBL] [Abstract][Full Text] [Related]
45. Radiation-activated secretory proteins of
Ban Y; Markowitz GJ; Zou Y; Ramchandani D; Kraynak J; Sheng J; Lee SB; Wong STC; Altorki NK; Gao D; Mittal V
Nat Cancer; 2021 Sep; 2(9):919-931. PubMed ID: 34917944
[TBL] [Abstract][Full Text] [Related]
46. Interleukin-1beta triggers the expansion of circulating granulocytic myeloid-derived suppressor cell subset dependent on Erk1/2 activation.
Shi H; Qin Y; Tian Y; Wang J; Wang Y; Wang Z; Lv J
Immunobiology; 2022 Jan; 227(1):152165. PubMed ID: 34936966
[TBL] [Abstract][Full Text] [Related]
47. Circulating myeloid-derived suppressors cells correlate with clinicopathological characteristics and outcomes undergoing neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
Wen T; Su C; Cheng X; Wang Y; Ma T; Bai Z; Zhang H; Liu Z
Clin Transl Oncol; 2022 Jun; 24(6):1184-1194. PubMed ID: 34988921
[TBL] [Abstract][Full Text] [Related]
48. Recruited monocytic myeloid-derived suppressor cells promote the arrest of tumor cells in the premetastatic niche through an IL-1β-mediated increase in E-selectin expression.
Shi H; Zhang J; Han X; Li H; Xie M; Sun Y; Liu W; Ba X; Zeng X
Int J Cancer; 2017 Mar; 140(6):1370-1383. PubMed ID: 27885671
[TBL] [Abstract][Full Text] [Related]
49. Immunosuppressive effects and mechanisms of three myeloid-derived suppressor cells subsets including monocytic-myeloid-derived suppressor cells, granulocytic-myeloid-derived suppressor cells, and immature-myeloid-derived suppressor cells.
Nagatani Y; Funakoshi Y; Suto H; Imamura Y; Toyoda M; Kiyota N; Yamashita K; Minami H
J Cancer Res Ther; 2021; 17(4):1093-1100. PubMed ID: 34528569
[TBL] [Abstract][Full Text] [Related]
50. IL-18 enhances immunosuppressive responses by promoting differentiation into monocytic myeloid-derived suppressor cells.
Lim HX; Hong HJ; Cho D; Kim TS
J Immunol; 2014 Dec; 193(11):5453-60. PubMed ID: 25362180
[TBL] [Abstract][Full Text] [Related]
51. Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs.
Lepper A; Bitsch R; Özbay Kurt FG; Arkhypov I; Lasser S; Utikal J; Umansky V
Oncoimmunology; 2023; 12(1):2247303. PubMed ID: 37593676
[TBL] [Abstract][Full Text] [Related]
52. Cardioprotective Role of Myeloid-Derived Suppressor Cells in Heart Failure.
Zhou L; Miao K; Yin B; Li H; Fan J; Zhu Y; Ba H; Zhang Z; Chen F; Wang J; Zhao C; Li Z; Wang DW
Circulation; 2018 Jul; 138(2):181-197. PubMed ID: 29437117
[TBL] [Abstract][Full Text] [Related]
53. Yeast-Derived Particulate β-Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer.
Albeituni SH; Ding C; Liu M; Hu X; Luo F; Kloecker G; Bousamra M; Zhang HG; Yan J
J Immunol; 2016 Mar; 196(5):2167-80. PubMed ID: 26810222
[TBL] [Abstract][Full Text] [Related]
54. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
Zhao Z; Gao Y; Xue Q; Gao S; He J
Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
[TBL] [Abstract][Full Text] [Related]
55. CD33
Sun Y; Shao J; Jiang F; Wang Y; Yan Q; Yu N; Zhang J; Zhang J; Li M; He Y
Am J Reprod Immunol; 2019 Jan; 81(1):e13067. PubMed ID: 30375700
[TBL] [Abstract][Full Text] [Related]
56. The Role of Myeloid-Derived Suppressor Cells in Tumor Growth and Metastasis.
Bayik D; Lee J; Lathia JD
Exp Suppl; 2022; 113():189-217. PubMed ID: 35165865
[TBL] [Abstract][Full Text] [Related]
57. Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis.
Franken A; Van Mol P; Vanmassenhove S; Donders E; Schepers R; Van Brussel T; Dooms C; Yserbyt J; De Crem N; Testelmans D; De Wever W; Nackaerts K; Vansteenkiste J; Vos R; Humblet-Baron S; Lambrechts D; Wauters E
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171010
[TBL] [Abstract][Full Text] [Related]
58. Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.
Gaißler A; Bochem J; Spreuer J; Ottmann S; Martens A; Amaral T; Wagner NB; Claassen M; Meier F; Terheyden P; Garbe C; Eigentler T; Weide B; Pawelec G; Wistuba-Hamprecht K
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286306
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of immune checkpoint inhibitor therapy in patients with
Bhandari NR; Hess LM; Han Y; Zhu YE; Sireci AN
Immunotherapy; 2021 Aug; 13(11):893-904. PubMed ID: 34139897
[TBL] [Abstract][Full Text] [Related]
60. Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors.
Bronte G; Verlicchi A; De Matteis S; Rossi A; Affatato A; Sullo FG; Gianni C; Canale M; Burgio MA; Delmonte A; Milella M; Crinò L
Front Immunol; 2021; 12():672219. PubMed ID: 34122429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
